Evaluation of the Effect of GnRH Analogue, Progesterone and Tolfenamic Acid on Serum Progesterone Profile and Conception Rate in Repeat Breeding Crossbred Cattle

Abstract

Secretion of prostaglandin F2α at the time of maternal recognition of pregnancy leads to embryonic loss. Early embryonic losses are one of the important causes of repeat breeding which increases the calving interval and leads to economic losses to farmers. Non-steroidal anti-inflammatory drugs inhibit the synthesis of PGF2α. The present study was designed to study the effect of treatment by GnRH analogue - Buserelin acetate, Progesterone (P4) and Tolfenamic acid on 32 repeat-breeding crossbred cattle aged 3-8 years. All the animals were randomly divided into 4 equal groups (n=8). Group 1 was taken as positive control i.e. inseminated on spontaneous estrous without any therapy. Group 2 animals were treated with injection Buserelin acetate @ 20 µg intramuscular (IM) at the time of artificial insemination (AI). Group 3 animals were treated with inj. Buserelin acetate @ 20 µg intramuscular at the time of AI followed by Injection P4 @100mg IM on days 4, 5, 6 after AI. Group 4 animals were treated with inj. Buserelin acetate @ 20 µg IM at the time of AI, inj. P4 @ 100mg IM on days 4, 5, 6 and inj. Tolfenamic acid @4 mg/kg body weight IM on days 16, 17, 18 after AI. Blood samples were collected from all the cows at day 0, 7, 16, 17, 18 of the estrous cycle for the study of serum progesterone profile. The conception rate observed in groups 1, 2, 3 and 4 were 12.5%, 37.5%, 50% and 75% respectively. Highest conception was observed in group 4 in which, combinations of Buserelin acetate, Exogenous P4 and Tolfenamic acid was administered. The study concluded that combination of Buserelin acetate, Exogenous P4 and Tolfenamic acid therapy helps to maintain the P4 level and significantly increases the conception rate by 6 times than control group.